HD204

HD204 is a proposed bevacizumab biosimilar from Korean developer Prestige Biopharma that just met its Phase 3 primary endpoint. The SAMSON-II trial (NCT03390686) reported positive topline equivalence data on March 24, 2026, with ORR at Week 18 of 48.7% for HD204 versus 46.5% for EU-licensed Avastin and a risk ratio of 1.047 (95% CI 0.86-1.27), well inside the prespecified equivalence margin [1][6]. The commercial bet is not on novel biology - bevacizumab has been blocking VEGF since FDA approval in 2004 - but on whether Prestige and its commercialization partner Intas Pharmaceuticals/Accord Healthcare can carve out share in a bevacizumab biosimilar market already crowded with Amgen's Mvasi, Pfizer's Zirabev, Celltrion's Vegzelma, Bio-Thera's Avzivi and Amneal/mAbxience's Alymsys [3][7]. For Prestige, this is the larger of two oncology biosimilar plays (the other being HD201, a trastuzumab biosimilar). Approval matters less for science and more for whether a small Korean company plus an Indian generics partner can build distribution into markets where the incumbents are entrenched and prices have already collapsed.

HD204 is at Phase 3 with positive topline data in hand. Prestige announced on 2026-03-24 that SAMSON-II met its primary endpoint of ORR at Week 18 in 625 patients across 91 centers in 15 countries; secondary endpoints (PFS, OS) were comparable between arms and safety was consistent with the bevacizumab reference [6]. A randomized Phase 1 three-arm PK study comparing HD204 to EU- and US-sourced bevacizumab was published in PLoS One in 2021 by Demarchi et al. and showed PK equivalence across the standard 90% confidence interval bounds [1]. No FDA designations apply here - biosimilars don't get breakthrough or fast track; they go through the 351(k) pathway in the US and the EMA's similar biological pathway in Europe. Per the partner Pearce IP commentary, marketing authorisation applications for HD204 are expected in H2 2026 in the US and EU [8]. The reference product, Avastin, lost US patent exclusivity in 2019 and EU exclusivity in 2022, so the regulatory runway is open. HD204 does not yet have a Korean MFDS approval; the company has not disclosed any approvals in Asia-Pacific markets as of writing. Commercial geography is now anchored by the 2022 Intas/Accord partnership covering the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS, and SEA - Prestige retains development and supply, Intas/Accord runs commercialization [7].

Bevacizumab targets VEGF-A, a protein tumors secrete to recruit new blood vessels. Cancers can't grow past a few millimeters without their own blood supply, so they hijack the body's normal blood-vessel-building machinery by pumping out VEGF-A, which acts like a help-wanted ad for endothelial cells (the cells lining blood vessel walls) [4]. Bevacizumab is a humanized monoclonal antibody that binds circulating VEGF-A and prevents it from docking onto its receptors on endothelial cells. Block the signal, starve the tumor - that's the whole pitch. The mechanism is as validated as any target in oncology: Avastin generated peak sales above $7 billion before biosimilar erosion and is approved across colorectal, lung, ovarian, cervical, renal, and brain cancers [3]. For a biosimilar, validation of the mechanism isn't the question - validation of structural and functional sameness is. HD204 has to demonstrate matched binding affinity, matched neutralization potency, matched glycosylation patterns, and matched PK/PD before clinical equivalence is even considered relevant. The analytical and PK comparability work has been published and the clinical equivalence step has now read out positive.

SAMSON-II (NCT03390686) was a randomized, double-blind equivalence trial comparing HD204 plus paclitaxel/carboplatin to EU-licensed Avastin plus the same chemotherapy backbone in first-line metastatic non-squamous NSCLC [2]. The primary endpoint was best overall response rate (ORR) at Week 18, with equivalence margins typical of biosimilar trials in this indication. Enrollment ran to 625 patients across 91 centers in 15 countries [6]. The trial met its primary endpoint with ORR 48.7% (HD204) vs 46.5% (Avastin), risk ratio 1.047 (95% CI 0.86-1.27) and risk difference 0.022 (95% CI -0.07 to 0.11), both within the predefined equivalence range [6]. Treatment-related adverse events were 33.9% (HD204) vs 34.4% (Avastin) with no new safety signals. The design is the standard biosimilar registrational read - ORR is sensitive enough to detect differences but doesn't require the years of follow-up that OS would. The one structural concern is that NSCLC bevacizumab use has declined since 2019 as IO-chemo combinations (immunotherapy plus chemotherapy, now the standard first-line treatment in most non-squamous NSCLC patients) became the standard of care, which may complicate post-approval commercial uptake even though the trial reads out positive.

Our model gives this drug a 14% chance of eventually being approved. That starts from the historical approval rate for Phase 3 drugs in this area - about 48% - then adjusts based on ten facts about the trial and its sponsor. The number is pulled down mainly by the sponsor's weak or thin approval track record, heavier-than-usual blinding, and weak or limited earlier-phase results; it gets a partial lift from having more secondary endpoints than is typical at this stage. The remaining factors are close to average and leave the estimate roughly where the base rate set it.

The clinical risk is now retired (Phase 3 met). The commercial risk is high. Five bevacizumab biosimilars already have FDA approval - Mvasi (Amgen, 2017), Zirabev (Pfizer, 2019), Alymsys (Amneal/mAbxience, 2022), Vegzelma (Celltrion, 2022), and Avzivi (Bio-Thera, 2023) [3]. US bevacizumab pricing has fallen materially from Avastin's peak, with the global biosimilar bevacizumab market estimated at roughly $1.5-1.8B in 2024 [9] - meaning Prestige and Intas are entering as the sixth or seventh biosimilar into a market that is no longer dollar-rich and whose share is split across multiple sellers with established hospital contracts and 340B (a US federal drug discount program that gives covered hospitals use to negotiate biosimilar pricing aggressively) logistics. Intas/Accord brings real commercial infrastructure in the US, EU, Canada, and emerging markets [7], which is the strongest commercial asset HD204 has - without it, this would be an Asia-only play. The other commercial risk is indication erosion: NSCLC bevacizumab use is shrinking as IO-chemo combinations dominate first line. Colorectal and ovarian uses remain, but those segments are also fully biosimilar-covered. Execution risk now centers on MAA submission timing (Prestige guides H2 2026 [8]), FDA/EMA inspection of the production site, and Intas/Accord's ability to win formulary positions in a market with established incumbents. Open Prestige financial-runway risk: the company is listed on the Korea Exchange (KRX:950210, not Euronext) with a market cap on the order of KRW 160 billion (~$120M USD) as of late 2025 - small enough that any delay in commercialization cash flow matters [10].

Upgrade from 'watch, don't get excited' to 'watch, with one specific catalyst left'. SAMSON-II met its primary endpoint cleanly [6], which was the highest-magnitude single binary risk on the asset. What is not yet de-risked: (a) MAA filings in the US and EU expected H2 2026 [8], (b) the FDA/EMA manufacturing inspection of the Busan production site, (c) Intas/Accord's commercial launch execution against five entrenched bevacizumab biosimilars. The relevant catalysts to track are now BLA/MAA filing announcements, FDA acceptance letters, and first commercial launch milestones in the Intas/Accord territories. The PLoS One PK paper [1] and the SAMSON-II topline [6] are already in the public domain so the science is largely told. For an investor screening biotech pipelines, HD204 is a low-conviction, low-asymmetry name - the upside is modest geographic share in a commoditized market where total biosimilar dollar volume is roughly $1.5-1.8B globally and shrinking on a per-unit basis, and the downside is being late to a crowded biosimilar segment. Prestige's small market cap means even modest commercial wins move the equity, but the same small cap is the reason runway risk has to be sized before any positive call.